RxDoctor Payments Data

Wendy Pone, NP

Nurse Practitioner · Cartersville, GANPI 1548810310

Payments from drug & device makers

$4,044in general payments, 2019–2025

Across 191 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$735
  • AstraZeneca$587
  • Novartis$548
  • Pfizer$323
  • Actelion Pharmaceuticals US, Inc.$291
  • Lexicon Pharmaceuticals, Inc.$250
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,044100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,044 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$28,579
Medicare patients
141
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban87$82,310
XareltoRivaroxaban45$38,326
FarxigaDapagliflozin Propanediol31$33,874
EntrestoSacubitril/Valsartan25$32,305
JardianceEmpagliflozin15$16,689
BrilintaTicagrelor15$11,652
Potassium Chloride91$6,136
Torsemide68$2,383
Ranolazine ErRanolazine17$1,421
Atorvastatin Calcium179$1,279
Metoprolol Succinate71$1,190
ClopidogrelClopidogrel Bisulfate91$1,111
Furosemide209$1,108
Bumetanide21$1,087
Hydralazine Hcl45$818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$323$82,31087 claims
AstraZenecaFarxiga, Brilinta$587$45,52646 claims
Johnson & JohnsonXarelto$131$38,32645 claims
NovartisEntresto$548$32,30525 claims
Boehringer IngelheimJardiance$32$16,68915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Cartersville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →